Shanghai InnoStar Bio-tech Co., Ltd. (SHA:688710)
56.80
-1.80 (-3.07%)
At close: Feb 2, 2026
SHA:688710 Balance Sheet
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
Cash & Equivalents | 1,254 | 1,370 | 1,158 | 1,255 | 638.77 | 198.64 |
Short-Term Investments | - | - | - | - | 12.33 | 2.43 |
Cash & Short-Term Investments | 1,254 | 1,370 | 1,158 | 1,255 | 651.1 | 201.07 |
Cash Growth | -15.47% | 18.25% | -7.69% | 92.70% | 223.82% | -5.55% |
Accounts Receivable | 346.75 | 359.88 | 273.91 | 228.07 | 139.5 | 47.03 |
Other Receivables | 8.12 | 22.74 | 17.81 | 6.06 | - | - |
Receivables | 354.87 | 382.62 | 291.72 | 234.13 | 139.54 | 47.17 |
Inventory | 431.3 | 332.02 | 510.54 | 489.47 | 396.85 | 212.99 |
Other Current Assets | 86.35 | 83.83 | 25.51 | 34.48 | 68.05 | 58.69 |
Total Current Assets | 2,127 | 2,168 | 1,986 | 2,013 | 1,256 | 519.92 |
Property, Plant & Equipment | 736.53 | 703.96 | 438.88 | 444.53 | 443.69 | 148.29 |
Other Intangible Assets | 103.44 | 105.52 | 109.47 | 10.91 | 5.39 | 3.3 |
Long-Term Deferred Tax Assets | 26.21 | 17.94 | 13.21 | 7.78 | 7.58 | 1.54 |
Long-Term Deferred Charges | 63.65 | 70.45 | 77.02 | 81.57 | 73.78 | 79.08 |
Other Long-Term Assets | 117.44 | 153.65 | 150.86 | 60.72 | 16.62 | 4.54 |
Total Assets | 3,174 | 3,220 | 2,775 | 2,618 | 1,803 | 756.68 |
Accounts Payable | 78.29 | 46.82 | 83.99 | 59.4 | 83.53 | 41.57 |
Accrued Expenses | 22.86 | 38.99 | 75.29 | 65.6 | 60.73 | 34.47 |
Short-Term Debt | - | 0.5 | 8.01 | - | - | - |
Current Portion of Long-Term Debt | - | - | - | - | 39.06 | 0.06 |
Current Portion of Leases | 13.59 | 29.28 | 23.39 | 17.57 | 17.91 | - |
Current Income Taxes Payable | 4.44 | 5.12 | 2.98 | 7.13 | 9.46 | 4.88 |
Current Unearned Revenue | 390.59 | 347.3 | 607.29 | 722 | 534.11 | 341.14 |
Other Current Liabilities | 116.65 | 100.35 | 80.36 | 30 | 20.76 | 4.78 |
Total Current Liabilities | 626.42 | 568.37 | 881.31 | 901.71 | 765.57 | 426.91 |
Long-Term Debt | - | - | - | - | - | 39 |
Long-Term Leases | 111.79 | 201.32 | 215.1 | 229.23 | 239.28 | - |
Long-Term Unearned Revenue | 60.04 | 41.34 | 38.78 | 45.76 | 43.34 | 53.1 |
Other Long-Term Liabilities | 0.84 | 6.39 | 0.76 | - | 0 | 0.2 |
Total Liabilities | 799.08 | 817.42 | 1,136 | 1,177 | 1,048 | 519.21 |
Common Stock | 140.98 | 140.98 | 105.73 | 105.73 | 87.13 | 59.31 |
Additional Paid-In Capital | 1,694 | 1,688 | 1,098 | 1,081 | 475.48 | 112.83 |
Retained Earnings | 502.7 | 562.6 | 414.83 | 220.38 | 134.38 | 65.33 |
Comprehensive Income & Other | -0.14 | 0.06 | - | - | - | - |
Total Common Equity | 2,337 | 2,392 | 1,618 | 1,407 | 696.99 | 237.47 |
Minority Interest | 37.98 | 10.19 | 21.42 | 34.35 | 57.43 | - |
Shareholders' Equity | 2,375 | 2,402 | 1,639 | 1,442 | 754.41 | 237.47 |
Total Liabilities & Equity | 3,174 | 3,220 | 2,775 | 2,618 | 1,803 | 756.68 |
Total Debt | 125.38 | 231.1 | 246.5 | 246.8 | 296.25 | 39.06 |
Net Cash (Debt) | 1,129 | 1,138 | 911.73 | 1,008 | 354.85 | 162.01 |
Net Cash Growth | -8.76% | 24.87% | -9.54% | 184.03% | 119.03% | -1.10% |
Net Cash Per Share | 7.74 | 9.71 | 8.63 | 10.42 | 4.83 | 2.74 |
Filing Date Shares Outstanding | 140.98 | 140.98 | 105.73 | 96.72 | 87.13 | 59.15 |
Total Common Shares Outstanding | 140.98 | 140.98 | 105.73 | 96.72 | 87.13 | 59.15 |
Working Capital | 1,500 | 1,600 | 1,105 | 1,111 | 489.97 | 93 |
Book Value Per Share | 16.58 | 16.97 | 15.30 | 14.55 | 8.00 | 4.01 |
Tangible Book Value | 2,234 | 2,286 | 1,509 | 1,396 | 691.59 | 234.17 |
Tangible Book Value Per Share | 15.84 | 16.22 | 14.27 | 14.44 | 7.94 | 3.96 |
Buildings | - | 103.59 | 44.04 | 25.53 | 24.35 | - |
Machinery | - | 379.74 | 316.83 | 288.03 | 223.18 | 180.35 |
Construction In Progress | - | 239.02 | 40.75 | 0.28 | 0.3 | - |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.